IF AAV-delivered shRNA targeting macroH2A1.2 (H2AFY2; single IP dose, 1×10¹² vg, AAV9 serotype, ~1.8 kb shRNA expression cassette, well within the 4.7 kb AAV packaging limit) combined with pyridostatin (PDS; 10 mg/kg IP 3×/wk × 4 weeks) is administered to ATRX-null ALT-positive osteosarcoma xenograft-bearing NSG mice (n ≥ 8/group, male/female balanced, 6–8 weeks old, U2OS or SAOS-2 flank xenograft),

THEN ≥70% reduction in ALT-associated PML bodies (APBs), ≥70% reduction in C-circle abundance, and ≥50% reduction in telomeric G-loop (G4/R-loop composite) signal versus untreated controls at 4 weeks, accompanied by ≥40% reduction in tumor volume relative to vehicle controls, will be observed by immunofluorescence-FISH (co-localization of PML + TelG probes), C-circle assay (slot blot), proximity ligation for G-loops, and caliper measurement respectively,

BECAUSE the following mechanistic chain links ATRX loss to macroH2A1.2-dependent ALT scaffolding that is simultaneously exploitable by G4 trapping:

1. ATRX loss in osteosarcoma removes the helicase/chromatin remodeler that normally resolves G-quadruplex structures and replication stress at telomeric repeats, permitting aberrant deposition of the histone variant macroH2A1.2 at stalled replication forks within telomeres — (ATRX loss permits macroH2A1.2 accumulation at RS-telomere sites and its deposition is coordinated by DDR signaling downstream of ATRX deficiency)[https://doi.org/10.1038/s41594-019-0192-3]

2. Aberrantly deposited macroH2A1.2 at telomeres provides the structural chromatin scaffold required for APB nucleation and ALT-associated homologous recombination — (macroH2A1.2 links ATRX loss to the ALT phenotype and its telomeric enrichment is mechanistically upstream of APB assembly)[https://doi.org/10.1038/s41594-019-0192-3]

3. Within these APBs, telomeric G-quadruplex structures co-localize with TERRA R-loops to form composite G-loop structures that serve as the recombination substrate for ALT-HDR; sublethal G4 stabilization with PDS enriches and traps these G-loops at telomeres, stalling ALT-HDR progression — (G4s and R-loops couple into composite G-loop structures detectable at ALT telomeres; sublethal G4 stabilization with a ligand enriches G-loops and perturbs ALT)[https://doi.org/10.1093/narcan/zcab031]

4. Critically, ATRX re-expression in the presence of a G4-stabilizing ligand is IMPAIRED in suppressing ALT — the original combined strategy of restoring full-length ATRX plus adding PDS is mechanistically contradictory because G4 stabilization blocks ATRX's own G4-resolving activity — (stabilizing G-quadruplex DNA impairs ATRX-dependent ALT suppression, meaning PDS antagonizes the very ATRX-mediated mechanism it is intended to complement)[https://doi.org/10.1038/ncomms8538] [SPECULATIVE implication for the original hypothesis: this represents a previously unappreciated antagonism in the PDS + ATRX restoration combination]

5. By contrast, macroH2A1.2 shRNA depletion acts DOWNSTREAM...

SENS category: OncoSENS

Key references: • doi.org/10.1038/s41594-019-0192-3] • doi.org/10.1093/narcan/zcab031] • doi.org/10.1038/ncomms8538] • doi.org/10.1101/gad.333963.119] • doi.org/10.1093/nar/gkac113]